Cargando…
Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145154/ https://www.ncbi.nlm.nih.gov/pubmed/37109654 http://dx.doi.org/10.3390/medicina59040696 |
_version_ | 1785034265130434560 |
---|---|
author | Stanciu, Ioana-Miruna Pirlog, Cristina Florina Anghel, Andrei-Wilhelm Parosanu, Andreea Ioana Olaru, Cristina Mihaela Orlov-Slavu, Cristina Iaciu, Ion Cristian Popa, Ana Maria Vrabie, Radu Constantin Nitipir, Cornelia |
author_facet | Stanciu, Ioana-Miruna Pirlog, Cristina Florina Anghel, Andrei-Wilhelm Parosanu, Andreea Ioana Olaru, Cristina Mihaela Orlov-Slavu, Cristina Iaciu, Ion Cristian Popa, Ana Maria Vrabie, Radu Constantin Nitipir, Cornelia |
author_sort | Stanciu, Ioana-Miruna |
collection | PubMed |
description | Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exist to help guide second-line treatment. Moreover, there is a scarcity of data on rechallenge treatment strategies with another CDK4/6 inhibitor after prior limiting toxicity. We report a real-world experience of rechallenging with abemaciclib after the prior reaction of grade 4 liver toxicity to ribociclib, with high transaminases values of more than 27 times the upper limit of normal (ULN) and unexpected grade 3 neutropenia and diarrhea after a few months of abemaciclib. After two years of treatment, the patient had stable oncological disease, with normal complete blood count, hepatic enzymes, and a very good performance status. We believe that our clinical case, along with others gathered from all around the world, will help with the consolidation of an unmet clinical need to readjust the treatment after experiencing toxicity to CDK4/6 inhibitors. |
format | Online Article Text |
id | pubmed-10145154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101451542023-04-29 Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review Stanciu, Ioana-Miruna Pirlog, Cristina Florina Anghel, Andrei-Wilhelm Parosanu, Andreea Ioana Olaru, Cristina Mihaela Orlov-Slavu, Cristina Iaciu, Ion Cristian Popa, Ana Maria Vrabie, Radu Constantin Nitipir, Cornelia Medicina (Kaunas) Case Report Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Following progression, no prospective randomized data exist to help guide second-line treatment. Moreover, there is a scarcity of data on rechallenge treatment strategies with another CDK4/6 inhibitor after prior limiting toxicity. We report a real-world experience of rechallenging with abemaciclib after the prior reaction of grade 4 liver toxicity to ribociclib, with high transaminases values of more than 27 times the upper limit of normal (ULN) and unexpected grade 3 neutropenia and diarrhea after a few months of abemaciclib. After two years of treatment, the patient had stable oncological disease, with normal complete blood count, hepatic enzymes, and a very good performance status. We believe that our clinical case, along with others gathered from all around the world, will help with the consolidation of an unmet clinical need to readjust the treatment after experiencing toxicity to CDK4/6 inhibitors. MDPI 2023-04-01 /pmc/articles/PMC10145154/ /pubmed/37109654 http://dx.doi.org/10.3390/medicina59040696 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Stanciu, Ioana-Miruna Pirlog, Cristina Florina Anghel, Andrei-Wilhelm Parosanu, Andreea Ioana Olaru, Cristina Mihaela Orlov-Slavu, Cristina Iaciu, Ion Cristian Popa, Ana Maria Vrabie, Radu Constantin Nitipir, Cornelia Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title_full | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title_fullStr | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title_full_unstemmed | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title_short | Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review |
title_sort | does the rechallenge with another cdk 4/6 inhibitor in breast cancer work? a case report and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10145154/ https://www.ncbi.nlm.nih.gov/pubmed/37109654 http://dx.doi.org/10.3390/medicina59040696 |
work_keys_str_mv | AT stanciuioanamiruna doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT pirlogcristinaflorina doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT anghelandreiwilhelm doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT parosanuandreeaioana doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT olarucristinamihaela doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT orlovslavucristina doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT iaciuioncristian doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT popaanamaria doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT vrabieraduconstantin doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview AT nitipircornelia doestherechallengewithanothercdk46inhibitorinbreastcancerworkacasereportandliteraturereview |